On a relative basis, the stock has outperformed the S&P 500 by 56.19% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.33% in the last 1 week, and is up 53.02% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 24.62% and the 50-Day Moving Average is 40.86%.The 200 Day SMA reached 64.28% Mast Therapeutics, Inc. is up 43.02% in the last 3-month period. Year-to-Date the stock performance stands at 46.43%.
Mast Therapeutics (MSTX) : 3 investment research analysts covering Mast Therapeutics (MSTX) have an average price target of $2.67 for the near short term. The highest target price given by the Brokerage Firm to the stock is $5 and the lowest target is $1 for the short term. Analysts expect the variance to be within $2.08 of the average price.
For the current week, the company shares have a recommendation consensus of Buy. Mast Therapeutics (NYSEMKT:MSTX): The stock opened at $0.59 and touched an intraday high of $0.615 on Friday. During the day, the stock corrected to an intraday low of $0.52, however, the bulls stepped in and pushed the price higher to close in the green at $0.615 with a gain of 7.91% for the day. The total traded volume for the day was 5,956,873. The stock had closed at $0.615 in the previous trading session.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).